Sandoz

(IN BRIEF) Sandoz Group AG, a Novartis spin-off, officially listed its shares at the SIX Swiss Exchange. With an opening share price of CHF 24.00, the market capitalization of Sandoz reached approximately CHF 10.3 billion. Sandoz’s issued share capital consists … Read the full press release →

(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz Group AG shares and ADRs scheduled to begin on October 4, 2023. This comes after receiving shareholder approval and key … Read the full press release →

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has successfully acquired the worldwide brand rights for the systemic antifungal agent Mycamine® (micafungin sodium) from Astellas. This acquisition bolsters Sandoz’s position in the global hospital sector and enhances … Read the full press release →

(IN BRIEF) Sandoz to commercialize six products exclusively in the US following distribution and collaboration agreement with Adalvo. The products are aimed at treating disorders that affect millions of people in the US each year, including antifungal/antibiotic, oncology, and pulmonary. … Read the full press release →

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a new biologics production plant in Lendava, Slovenia, in a move expected to be worth at least USD 400 million. The … Read the full press release →

(NOTICIA EN BREVE) Gilbert Ghostine ha sido designado presidente designado de la nueva junta directiva de Sandoz, tras el anuncio de la junta directiva de Novartis. La nueva Junta Directiva de Sandoz se formará en la segunda mitad de 2023, … Read the full press release →

(IN BRIEF) Gilbert Ghostine has been appointed as Chairman-designate of the new Board of Directors of Sandoz, following the announcement by Novartis Board of Directors. The new Board of Directors of Sandoz will be formed in the second half of … Read the full press release →

(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine® (micafungin sodium, Funguard® in Japan) from Astellas. This acquisition will reinforce Sandoz’s hospital … Read the full press release →

(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los derechos de producto a nivel mundial del agente antifúngico sistémico líder Mycamine® (micafungina sódica, Funguard® en Japón) de Astellas. Esta … Read the full press release →